Life-Saving Meningococcal Vaccine on the Horizon
A groundbreaking research project led by the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, has demonstrated the safety and effectiveness of a combination Men ABCWY vaccine. This vaccine, which covers all five common strains of meningococcal disease, could soon be available to provide universal protection for young adults and teenagers.
Key Findings:
- High Efficacy: The combination vaccine was highly effective in providing universal protection against meningococcal disease.
- Reduced Cases: The introduction of the Men ACWY vaccine in 2018 saw a significant reduction in cases caused by the W and Y strains, and the B variant became the most common cause of meningococcal in Australia.
- Cost-Effective: While meningococcal B vaccines have been shown to be safe and effective in children and young adults, the low incidence of the disease means it hasn’t been considered cost-effective for inclusion on the National Immunization Program (NIP).
Current Situation:
- Separate Vaccines: Parents wanting full protection against all five strains of meningococcal disease must purchase a separate Men B vaccine privately, which can be costly and may be out of reach for many families.
- Future Plans: The research aims to show that a combination ‘pentavalent’ vaccine containing the A, B, C, W, and Y strains of meningococcal in one injection is safe and would provide equivalent levels of immunity as the meningococcal B and Men ACWY vaccines given separately.
FDA Approval:
- The combination vaccine was recently approved by the FDA for use in the US for older children and young adults aged 10 to 25 years, and the researchers hope to see it licensed in Australia in the near future.
Future Goals:
- Replacement of Current Vaccine: The researchers aim to replace the current Men ACWY vaccine given to all teenagers in Year 10 at high schools throughout Australia.
- Safety and Efficacy for Babies and Toddlers: Future studies will focus on demonstrating the safety and efficacy of the vaccine for babies and toddlers, with the hope of future inclusion on the NIP from 12 months of age.
Conclusion:
This breakthrough could significantly reduce the incidence of meningococcal disease in children, providing parents with peace of mind and the highest possible protection against this devastating disease.
Provided by The Kids Research Institute Australia
Citation:
Researchers on the cusp of one-shot meningococcal protection (2025, May 1)
Retrieved 2 May 2025 from https://medicalxpress.com/news/2025-05-cusp-shot-meningococcal.html
Reference : https://medicalxpress.com/news/2025-05-cusp-shot-meningococcal.html
